Valacyclovir
This antiviral medication is a prodrug that is converted in the body into acyclovir, used to treat infections caused by herpes viruses including genital herpes, cold sores, shingles (herpes zoster), and chickenpox. It works by blocking the viral enzyme needed for the herpes virus to copy its DNA and reproduce. When taken daily as suppressive therapy, it can significantly reduce the frequency and severity of herpes outbreaks and lower the risk of transmitting the virus to others.
分子量
324.3400 g/mol
LogP
-0.90
TPSA
147.00 Ų
リピンスキーの五則
適合
治療領域
作用機序
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21
InChI
InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1
Molecular Formula
C13H20N6O4
HBD / HBA
3 / 7
回転可能結合数
8
重原子数
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
This antiviral medication is a prodrug that is converted in the body into acyclovir, used to treat infections caused by herpes viruses including genital herpes, cold sores, shingles (herpes zoster), and chickenpox. It works by blocking the viral enzyme needed for the herpes virus to copy its DNA and reproduce. When taken daily as suppressive therapy, it can significantly reduce the frequency and severity of herpes outbreaks and lower the risk of transmitting the virus to others.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Valacyclovir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1349. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135398742. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="valacyclovir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/valacyclovir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/valacyclovir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/valacyclovir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="valacyclovir"></drugfyi-drug>